Literature DB >> 27557073

[Autoimmune encephalitis].

Albrecht Günther, Julia Schubert, Dirk Brämer, Otto Wilhelm Witte.   

Abstract

Autoimmune encephalitis, an inflammatory disease of the brain, is usually attributed to antibody-mediated damage and dysfunction of neuronal structures. A distinction is made between onconeuronal antibodies (directed against intracellular neuronal antigens with resulting paraneoplastic neurological syndromes) and antibodies directed against neuronal cell surface proteins (with resulting synaptic encephalopathies). Anti-NMDA-Receptor-Encephalitis, the most common form of autoimmune encephalopathy, is characterized by a phased course of disease. Early disease phase involves nonspecific prodromes (fatigue, fever, headache) which lead to family doctor or emergency department consultation. Subsequently, neuropsychiatric behavioural problems, seizures, disturbance of memory and finally coma, dysautonomia and respiratory insufficiency often result in major complications (e.g. status epilepticus) necessitating intensive care treatment. The diagnosis is secured by detection of auto-antibodies in serum or cerebrospinal fluid. An intensive search for tumors is also recommended. The treatment of autoimmune encephalitis comprises of immunomodulatory and immunosuppessive strategies. Tumor therapy is the most important treatment of autoimmune encephalitis by onconeuronal antibodies. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27557073     DOI: 10.1055/s-0041-108858

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  Anti-GABAB receptor encephalitis in a patient with gastric adenocarcinoma.

Authors:  Xiao-Tao Jia; Yanfang Pan; Zhengli Di; Naibing Gu; Zhiqin Liu; Yu-Ming Kang
Journal:  Neurol Sci       Date:  2018-08-14       Impact factor: 3.307

Review 2.  Systematic Review: Syndromes, Early Diagnosis, and Treatment in Autoimmune Encephalitis.

Authors:  Christina Hermetter; Franz Fazekas; Sonja Hochmeister
Journal:  Front Neurol       Date:  2018-09-05       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.